Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.66 |
| ▸ | HTR2A | P28223 | 2/20 | 0.66 |
| ▸ | HTR1B | P28222 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888648 | 1.00 | SLC6A4 (0.66) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL3886782 | 1.00 | SLC6A4 (0.66) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL3886786 | 1.00 | SLC6A4 (0.66) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL3888644 | 1.00 | SLC6A4 (0.66) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL5787906 | 0.91 | HTR2A (0.64) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL5786564 | 0.91 | HTR2A (0.64) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL5786565 | 0.91 | HTR2A (0.64) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL6088177 | 0.80 | SLC6A4 (1.00) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL6087331 | 0.80 | SLC6A4 (1.00) | SLC6A4HTR2AHTR1BHTR1ADRD1 | |
| SCHEMBL6087829 | 0.80 | SLC6A4 (1.00) | SLC6A4HTR2AHTR1BHTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488751-B2 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20060160881-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060148881-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-Benzodioxan | WYETH (US) | 2006-07-06 | — | — | US | disclosed |
| US-7041697-B2 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1546151-B1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH CORP (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1546151-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6911445-B2 | For reatment of depression, childhood depression, dysthymia, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive-compulsive disorder, cocaine and alcohol addiction | WYETH (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1537103-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040171667-A1 | Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans | WYETH | 2004-09-02 | — | — | US | disclosed |
| US-20040127543-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH | 2004-07-01 | — | — | US | disclosed |
| WO-2004024732-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024723-A1 | ANTIDEPRESSANT CYCLOALKYLAMINE DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160881-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | HTR5A, OPRD1, DRD2 | SLC6A4 66/4885HTR2A 35/4885HTR1B 25/4885 |
| US-20040127543-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-benzodioxan | HTR5A, OPRD1, TAAR5 | SLC6A4 61/4885HTR2A 32/4885HTR1B 18/4885 |
| US-20060148881-A1 | Antidepressant cycloalkylamine derivatives of 2,3-dihydro-1,4-Benzodioxan | HTR5A, OPRD1, DRD2 | SLC6A4 66/4885HTR2A 35/4885HTR1B 25/4885 |
| US-20040171667-A1 | Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans | HTR5A, CRH, TPH1 | SLC6A4 76/4885HTR2A 45/4885HTR1B 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.